Scholar Rock Holding Corporation
SRRK
Kedudukan dalam Saham
#3423
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Harga Saham
$41.58
Modal Pasaran
$5.06B
Perubahan (1 hari)
3.34%
Perubahan (1 tahun)
48.94%
Negara
US
Perdagangan Scholar Rock Holding Corporation (SRRK)
Kategori
Healthcare
Bilangan saham terbitan bagi Scholar Rock Holding Corporation (SRRK)
Bilangan saham terbitan setakat June 2026: 130.61M
Menurut laporan kewangan terkini dan harga saham Scholar Rock Holding Corporation, bilangan saham terbitan semasa ialah 130.61M. Pada akhir December 2023, syarikat mempunyai 75.98M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Scholar Rock Holding Corporation (SRRK) dari 2016 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 130.61M | 30.82% |
| 2024 | 99.84M | 31.40% |
| 2023 | 75.98M | 27.46% |
| 2022 | 59.61M | 62.38% |
| 2021 | 36.71M | 19.45% |
| 2020 | 30.73M | 11.61% |
| 2019 | 27.54M | 75.90% |
| 2018 | 15.66M | -12.57% |
| 2017 | 17.91M | 0.00% |
| 2016 | 17.91M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 253.90M | 94.39% |
US
|
|
| 396.00M | 203.19% |
US
|
|
| 478.91M | 266.67% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -52.39% |
NL
|
